🔥 Breakout ↑ Rising
Business
Why Arrowhead Shot Sky-High, While Ionis Toppled
Arrowhead Pharmaceuticals sees a stock surge following positive Phase 3 trial results for its lipid-lowering drug, causing a decline for competitor Ionis.